Urol. praxi, 2011; 12(4): 208-212

Evaluation of prostate specific antigen changes in time

MUDr.Kamil Belej, Ph.D., FEBU, MUDr.Ondřej Kaplan, MUDr.Oto Kőhler, CSc., MUDr.Jiří Kočárek, Ph.D., MUDr.Pavel Drlík
Urologické oddělení ÚVN, Praha

Prostate specific antigen (PSA) belongs to the most important prognostic factors in prostate cancer. One of the parameters derived from

PSA is prostate specific antigen doubling time (PSADT). PSADT is coming from the same data as PSA velocity and represents the relative

rate of PSA change over time and is defined as the time needed for the PSA value to double. Although PSADT is used to predict outcomes

in prostate cancer, clinicians must know the method of its calculation. PSADT calculation requires logarithmic analysis of data because

it takes into account the exponential nature of neoplastic growth. Examples of computer based tool for displaying and calculation PSA

kinetics is presented in conjunction with method of data acquisition.

Keywords: prostate cancer, PSA, PSADT, calculation

Published: August 10, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Belej K, Kaplan O, Kőhler O, Kočárek J, Drlík P. Evaluation of prostate specific antigen changes in time. Urol. praxi. 2011;12(4):208-212.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Arlen PM, Bianco F, Dahut WL, et al. Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol 2008; 179(6): 2181-2185. Go to original source... Go to PubMed...
    2. Belej K, Kaplan O, Köhler O, Kočárek J, Drlík P. Možnosti modelování kinetiky prostatického specifického antigenu (abstrakt). Onkologie 2009; 3(Suppl B): 21-22.
    3. D'Amico AV, Moul JW, Carroll PR, et al. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 2003; 95(18): 1376-1383. Go to original source... Go to PubMed...
    4. Daskivich TJ, Regan MM, Oh WK. Prostate specific antigen doubling time calculation: not as easy as 1, 2, 4. J Urol 2006; 176(5): 1927-1937. Go to original source... Go to PubMed...
    5. Freedland SJ, Moul JW. Prostate specific antigen recurrence after definitive therapy. J Urol 2007; 177(6): 1985-1991. Go to original source... Go to PubMed...
    6. Hrabec M, Študent V, Grepl M, et al. PSA velocita a její význam pro včasnou diagnostiku ca prostaty. Urol praxi 2008; 9(6): 309-312.
    7. Jarolím L, Veselý Š, Antoch J, et al. Predikce charakteru elevace PSA při biochemické recidivě po radikální prostatektomii pomocí matematického modelu (abstrakt). Vybrané otázky onkologie XIII. Galén 2009: 111-112.
    8. Klotz LH. Active surveillance for good risk prostate cancer: rationale, method, and results. Can J Urol 2005; 12(Suppl 2): 21-24. Go to original source... Go to PubMed...
    9. Leibman BD, Dillioglugil O, Scardino PT, et al. Prostate specific antigen doubling times are similar in patients with recurrence after radical prostatectomy or radiotherapy: a novel analysis. J Clin Oncol 1998; 16: 2267-2271. Go to original source... Go to PubMed...
    10. Mermall H, Sothern RB, Kanabrocki EL, et al. Temporal (circadian) and functional relationship between prostatespecific antigen and testosterone in healthy men. Urology 1995; 46: 45-53. Go to original source... Go to PubMed...
    11. Ornstein DK, Smith DS, Rao GS, et al. Biological variation of total, free and percent free serum prostate specific antigen levels in screening volunteers. J Urol 1997; 157(6): 2179-2182. Go to original source... Go to PubMed...
    12. Pruthi RS, Johnstone I, Tu IP, Stamey TA. Prostate-specific antigen doubling times in patients who have failed radical prostatectomy: correlation with histologic characteristics of the primary cancer. Urology 1997; 49: 737-742. Go to original source... Go to PubMed...
    13. Ramírez ML, Nelson EC, Devere White RW, Lara PN Jr, Evans CP. Current applications for prostate-specific antigen doubling time. Eur Urol 2008; 54(2): 291-300. Go to original source... Go to PubMed...
    14. Scher HI, Eisenberger M, D'Amico AV, et al. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 2004; 22(3): 537-556. Go to original source... Go to PubMed...
    15. Schmid HP, McNeal JE, Stamey TA. Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer 1993; 71(6): 2031-2040. Go to original source... Go to PubMed...
    16. Veselý Š, Jarolím L, Babjuk M, Kaliská V, Schmidt M. Poměr PSA NADIR a času do PSA NADIR stanoveného ultrasenzitivním testem jako významný prediktor selhání radikální prostatektomie (abstrakt). Čes Urol 2010; 14(4): 247.

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.